Celltrion USA will present new analyses of ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis at ACG 2026. The findings highlight significant clinical outcomes.

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn’s disease and ulcerative colitis Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients with ileum-dominant Crohn’s disease JERSEY […]

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn's disease and ulcerative colitis and underscore Celltrion's commitment to adva...

Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its broader strategy to expand into the original drug market.

At the 2026 Digestive Disease Week, Celltrion is set to present seven significant abstracts highlighting advancements in managing inflammatory bowel diseases using innovative therapies.

Celltrion reveals compelling results from the LIBERTY-CD post-hoc analysis, demonstrating ZYMFENTRA's consistent efficacy across Crohn's disease sites. Read more!

At the 2025 DDW in San Diego, Celltrion will present six studies on IBD, focusing on ZYMFENTRA's effectiveness for Crohn's and ulcerative colitis.

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn's disease and ulcerative colitis and underscore Celltrion's...